| Drug Name: | Norfloxacin (70458-96-7) |
|---|---|
| PubChem ID: | 4539 |
| SMILES: | CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCNCC3)F)C(=O)O |
| InchiKey: | OGJPXUAPXNRGGI-UHFFFAOYSA-N |
| Therapeutic Category: | Anti-Bacterial Agents, Anti-Infective Agents, Antineoplastic Agents, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors, Enzyme Inhibitors, Nucleic Acid Synthesis Inhibitors, Topoisomerase II Inhibitors, Topoisomerase Inhibitors |
| Molecular Weight (dalton) | : | 319.336 |
| LogP | : | 1.2683 |
| Ring Count | : | 2 |
| Hydrogen Bond Acceptor Count | : | 5 |
| Hydrogen Bond Donor Count | : | 2 |
| Total Polar Surface Area | : | 74.57 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Warfarin (81-81-2) | Bleeding | Antagonistic | Uncertain. It is not clear what factors might have been responsible in those cases where the effects of the anticoagulants were increased | Norfloxacin and warfarin |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category